Bortezomib in combination with epirubicin, dexamethasone and thalidomide is a highly effective regimen in the treatment of multiple myeloma: A single-center experience

International Journal of Hematology

Volumn 89, Issue 1, 2009, Pages 34-38

  Lü, Shuqing ^a   Wang, Jianmin ^a   Xu, Xiaoqian ^a   Ni, Xiong ^a   Huang, Chongmei ^a   Qiu, Huiying ^a   Hu, Xiaoxia ^a   Yang, Jianmin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Dexamethasone; Epirubicin; Multiple myeloma; Thalidomide

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN; MELPHALAN; NAVELBINE; ONDANSETRON; PAMIDRONIC ACID; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEMUSTINE; THALIDOMIDE; VINCRISTINE; VINDESINE;

ADULT; ANOREXIA; ARTICLE; AUTOTRANSPLANTATION; CD34 SELECTION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONSTIPATION; CREATININE CLEARANCE; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; ECG ABNORMALITY; FEMALE; HUMAN; INFECTION; INSOMNIA; KIDNEY FAILURE; LIVER DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PERIPHERAL NEUROPATHY; SEPSIS; SEPTICEMIA; SKIN DEFECT; SWELLING; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WEAKNESS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; BORONIC ACIDS; DEXAMETHASONE; EPIRUBICIN; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; REMISSION INDUCTION; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 67049166479     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-008-0218-9     Document Type: Article

References (22)

1. NL Sharma VC Sharma VK Mahajan V Shanker N Ranjan M Gupta 2007 Thalidomide: an experience in therapeutic outcome and adverse reactions J Dermatolog Treat 21 1 6
2. MA Dimopoulos K Zervas G Kouvatseas 2001 Thalidomide and dexamethasone combination for refractory multiple myeloma Ann Oncol 12 991 5
3. T Hideshima P Richardson D Chauhan 2001 The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 3071 6
4. MH Ma HH Yang K Parker 2003 The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents Clin Cancer Res 9 1136 44
5. N Mitsiades CS Mitsiades PG Richardson 2003 The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications Blood 101 2377 80
6. PG Richardson B Barlogie J Berenson 2003 A phase 2 study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2609 17
7. RZ Orlowski A Nagler P Sonneveld 2007 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 3892 901
8. PG Richardson P Sonneveld M Schuster 2007 Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 3557 60
9. L Rosiñol A Oriol MV Mateos 2007 Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics J Clin Oncol 25 4452 8
10. H Freimann A Calderoni P Cornu R Olie 2007 Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland Swiss Med Wkly 137 317 22
11. SE Biehn DT Moore PM Voorhees 2007 Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin Ann Hematol 86 211 6
12. M Wang S Giralt K Delasalle B Handy R Alexanian 2007 Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma Hematology 12 235 9
13. M Kropff G Bisping E Schuck 2007 Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma Br J Haematol 138 330 7
14. B Barlogie R Desikan P Eddlemon 2001 Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients Blood 98 492 4
15. A Badros O Goloubeva R Fenton 2006 Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma Clin Lymphoma Myeloma 7 210 6
16. A Palumbo MT Ambrosini G Benevolo 2007 Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma Blood 109 2767 72
17. HE Oakervee R Popat N Curry 2005 PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma Br J Haematol 129 755 62
18. S Ciolli F Leoni F Gigli L Rigacci A Bosi 2006 Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients Leuk Lymphoma 47 171 3
19. A Badros O Goloubeva JS Dalal 2007 Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature Cancer 110 1042 9
20. S Jagannath BG Durie J Wolf 2005 Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Br J Haematol 129 776 83
21. Y Tong J Qian Y Li H Meng J Jin 2007 The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients Am J Hematol 82 403 4
22. O Enrico B Gabriele C Nadia 2007 Unexpected cardiotoxicity in haematological bortezomib treated patients Br J Haematol 138 396 7